Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A positive readout of a Rapport ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug ...

(RTTNews) - Rapport Therapeutics, Inc. (RAPP) said the U.S. FDA has cleared the company to advance RAP-219 into registrational trials, allowing accelerated initiation of its Phase 3 program in focal ...

Xcopri (cenobamate) and Keppra (levetiracetam) are prescribed to treat focal onset seizure. Keppra has additional uses. Keppra comes in several forms, but both drugs come as oral tablets. Keppra is ...

Robust efficacy, competitive tolerability and ease of administration. Those are the qualities for a potential blockbuster antiseizure medication, according to Abe Ceesay, CEO of Rapport Therapeutics ...

A video of Yareli Jessica Gijon having a seizure in class has gone viral reaching over 13 million views ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...